Anasuya Dighe

Anasuya Dighe

Auto-generated profile, based on publicly available information

Anasuya Dighe

Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Science Advances
Verified
Journal Article
Open access
QBQian Ba
Qian Ba
YHYuanyuan Hei
Yuanyuan Hei
ADAnasuya Dighe
Anasuya Dighe
WLWenxue Li
Wenxue Li
JMJamie Maziarz
Jamie Maziarz
YLYansheng Liu
Yansheng Liu
Evolutionary profiling has been largely limited to the nucleotide level. Using consistent proteomic methods, we quantified proteomic and phosphoproteomic layers in fibroblasts from 11 common mammalian species, with transcriptomes as reference. Covariation analysis indicates that transcript and protein expression levels and variabilities across mammals remarkably follow functional role, with extracellular matrix–associated expression being the most variable, demonstrating strong transcriptome-proteome coevolution. The biological variability of gene expression is universal at both interindividual and interspecies scales but to a different extent. RNA metabolic processes particularly show higher interspecies versus interindividual variation. Our results further indicate that while the ubiquitin-proteasome system is strongly conserved in mammals, lysosome-mediated protein degradation exhibits remarkable variation between mammalian lineages. In addition, the phosphosite profiles reveal a phosphorylation coevolution network independent of protein abundance.

19 February 2026 in Annals of Oncology
Verified
Journal Article
Open access
RMRobert Motzer
Robert Motzer
LALaurence ALBIGES
Laurence ALBIGES
SAS.A. Treviño Aguirre
S.A. Treviño Aguirre
RKR. Kanesvaran
R. Kanesvaran
PCP. Centkowski
P. Centkowski
TCT.K. Choueiri
T.K. Choueiri
Primary results from COSMIC-313 demonstrated significantly longer progression-free survival (PFS) with first-line cabozantinib plus nivolumab and ipilimumab versus placebo plus nivolumab and ipilimumab in patients with advanced renal cell carcinoma. Final efficacy and safety results, as well as data from exploratory biomarker analyses, are reported here. The design, participants, and primary-endpoint PFS outcomes have been reported previously for this phase III, double-blind, randomized (1 : 1) study of cabozantinib or placebo plus nivolumab and ipilimumab in adults with previously untreated, advanced clear cell renal cell carcinoma. The secondary endpoint was overall survival (OS) in the intention-to-treat population. Exploratory biomarker analyses investigated the potential association between immune cell types and gene signatures with clinical outcomes. After a median follow-up of 45.0 months, the updated median PFS in the cabozantinib (triplet) arm was longer than in the placebo (doublet) arm (16.6 versus 11.2 months; hazard ratio 0.82, 95% confidence interval 0.69-0.98). There was no significant difference in median OS (hazard ratio 1.02, 95% confidence interval 0.85-1.23, P = 0.84), and the safety profile was consistent with the earlier analysis (grade 3/4 treatment-related adverse events occurred in 75% and 43% of patients in the triplet and doublet arms, respectively). In patients with higher levels of M2-like macrophages, the triplet regimen was associated with significantly improved PFS and OS compared with the doublet regimen. Responders in the triplet arm exhibited elevated angiogenic signatures and reduced immune-related pathways, while responders in the doublet arm had robust immune activation. Long-term results from COSMIC-313 continue to demonstrate a PFS benefit with the addition of cabozantinib to nivolumab and ipilimumab. There was no OS benefit and no new safety signals were observed. Exploratory biomarker analyses suggest adding cabozantinib to nivolumab and ipilimumab improves survival in patients with high levels of M2-like macrophages.

30 August 2022 in Evolution, Medicine, and Public Health
Verified
Journal Article
Open access
PDF file
XMXinghong Ma
Xinghong Ma
ADAnasuya Dighe
Anasuya Dighe
JMJamie Maziarz
Jamie Maziarz
ENEdwin Neumann
Edwin Neumann
EEEric Erkenbrack
Eric Erkenbrack
GWGunter P. Wagner
Gunter P. Wagner
CD44 is an extracellular matrix receptor implicated in cancer progression. CD44 increases the invasibility of skin (SF) and endometrial stromal fibroblasts (ESF) by cancer and trophoblast cells. We reasoned that the evolution of CD44 expression can affect both, the fetal–maternal interaction through CD44 in ESF as well as vulnerability to malignant cancer through expression in SF. We studied the evolution of CD44 expression in mammalian SF and ESF and demonstrate that in the human lineage evolved higher CD44 expression. Isoform expression in cattle and human is very similar suggesting that differences in invasibility are not due to the nature of expressed isoforms. We then asked whether the concerted gene expression increase in both cell types is due to shared regulatory mechanisms or due to cell type-specific factors. Reporter gene experiments with cells and cis-regulatory elements from human and cattle show that the difference of CD44 expression is due to cis effects as well as cell type-specific trans effects. These results suggest that the concerted expression increase is likely due to selection acting on both cell types because the evolutionary change in cell type-specific factors requires selection on cell type-specific functions. This scenario implies that the malignancy enhancing effects of elevated CD44 expression in humans likely evolved as a side-effect of positive selection on a yet unidentified other function of CD44. A possible candidate is the anti-fibrotic effect of CD44 but there are no reliable data showing that humans and primates are less fibrotic than other mammals. While all multicellular organisms can develop tumors, cancer mortality is, to a large degree, determined by the tendency of tumors to progress to malignant cancer, i.e. the spread of cancer cells to other parts of the body. There are large differences in the rate of cancer malignancy, with many hoofed animals (cow, horses, etc.), for instance, less vulnerable to malignancy than say humans. In order to understand the species differences in cancer malignancy, we investigated the evolutionary changes in the expression of a gene that has been implicated in cancer malignancy, called CD44. We find that the primate lineage has evolved high levels of CD44 expression, while that in other animals remained comparatively modest. This result suggests that the expression of this gene might explain, in part, the human vulnerability to malignant cancer.

14 December 2018 in International Journal of Advances in Engineering Sciences and Applied Mathematics
Verified
Journal Article
Closed access
PDF file
VGVasundhara Gadiyaram
Vasundhara Gadiyaram
ADAnasuya Dighe
Anasuya Dighe
SVSaraswathi Vishveshwara
Saraswathi Vishveshwara

1 January 2015 in Biophysical Journal
Verified
Journal Article
Closed access
ADAnasuya Dighe
Anasuya Dighe
NCNagasuma Chandra
Nagasuma Chandra
SVSaraswathi Vishveshwara
Saraswathi Vishveshwara
GAG.K. Ananthasuresh
G.K. Ananthasuresh